On January 15, 2022, the second China artificial cornea online Summit Forum was held at 8:30 a.m. The meeting was hosted by the corneal disease Committee of Beijing ophthalmologist Association and the Department of Ophthalmology of the General Hospital of the Chinese people's Liberation Army, aiming to promote the healthy development of artificial cornea. The meeting focused on the indications and contraindications of corneal transplantation, the indications and case selection of Michaelis artificial cornea, the post-operative treatment and complication prevention of Michaelis artificial cornea, the clinical application of Michaelis artificial cornea and many other topics.
The artificial cornea designed, developed and produced by Beijing Mihe medical device Co., Ltd. has officially obtained the class III medical device registration certificate issued by the State Drug Administration. According to the public information on the official website of the State Food and drug administration, Michaelis artificial cornea is made of artificial materials without donor cornea, which helps to alleviate the current situation of scarce corneal donors in China and provides a new way for the clinical treatment of high-risk corneal transplantation patients.
Screenshot of the official website of the State Food and Drug Administration
At the same time, it can also save the cost of patients. Patients do not need to use expensive immunosuppressive drugs for a long time after operation, and rarely need local hormonal ophthalmic drugs, which greatly reduces the possibility of postoperative tissue nonunion, infection and hormonal glaucoma. Postoperative care is also relatively simple, which provides the greatest possibility for the maintenance of patients' visual function and the improvement of quality of life.
Michaelis artificial cornea
In addition, Michaelis artificial cornea also has breakthrough and innovation in implantation technology: it is reinforced with autologous ear cartilage. This reinforcement method can significantly improve the long-term implantation rate of the artificial cornea, and the longest clinical case has been more than 20 years.
China is a large country with corneal blindness, and there are 4 million patients with corneal blindness. It is gratifying that corneal blindness can be cured. More than 80% of patients with corneal blindness can recover their eyesight through routine donor corneal transplantation. However, about 15% of patients with corneal blindness are still high-risk corneal transplantation patients, and conventional corneal transplantation is difficult to succeed. With the approval of Michaelis artificial cornea on the market, it will bring opportunities for such people to recover their eyesight.
There are many differences between artificial corneal transplantation and conventional corneal transplantation. In order to standardize the clinical use of Michaelis artificial cornea and reduce surgical complications, the corneal disease Committee of Beijing ophthalmologist Association and the Department of Ophthalmology of the General Hospital of the Chinese people's Liberation Army specially held this meeting to provide a platform for communication and learning.
Participating experts
At the meeting, Professor Huang Yifei, director of Academic Committee of Ophthalmology Department of General Hospital of Chinese people's Liberation Army, Professor Wang Liqiang, deputy director of Ophthalmology Department of General Hospital of Chinese people's Liberation Army, Professor Pan Zhiqiang, director of eye bank of Beijing Tongren Hospital, Professor Shi Weiyun, chief physician of ophthalmology hospital affiliated to Shandong First Medical University Professor Xu Jianjiang, affiliated ophthalmology and otolaryngology Hospital of Fudan University, Professor Huang Ting, Zhongshan ophthalmology center of Sun Yat sen University, Professor Hong Jing, ophthalmology center of the Third Hospital of Peking University, Professor Chen Wei, affiliated ophthalmology hospital of Wenzhou Medical University, Professor Li Shaowei, Beijing Aier Yingzhi ophthalmology hospital, Professor Wu Huping, affiliated Xiamen ophthalmology center of Xiamen University, Professor Jie Ying, Beijing Tongren Hospital Professor Zhang Hong, ophthalmic hospital of the First Affiliated Hospital of Harbin Medical University, Professor Chen Baihua, Xiangya Second Hospital of Central South University, Professor Li Guigang, Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology, Professor Feng Yun, the Third Hospital of Peking University, Professor Zhao Shaozhen, ophthalmic hospital of Tianjin Medical University, Professor Wu Jie, the First Affiliated Hospital of Northwest University (Xi'an First Hospital) Professor Yang Yuli of the First Affiliated Hospital of the Army Medical University, Professor Li Wei of the Medical College of Xiamen University, Professor Zhang Mingchang of Wuhan Union Medical College, Professor Fu Yao of the Ninth People's Hospital Affiliated to the Medical College of Shanghai Jiaotong University Affiliated ophthalmic hospital of Shandong First Medical University (Professor Gao Hua of Shandong Eye Hospital, Professor Zhang Qi of the Affiliated Hospital of Chongqing Medical University, Professor Yang Yanning of the eye center of the people's Hospital of Wuhan University, Professor Gao Minghong of the northern theater general hospital, Professor Jin Xiuming of the eye center of the Second Affiliated Hospital of the Medical College of Zhejiang University, and Professor Wang Linnong of the first hospital of Nanjing gathered in the live broadcasting room to introduce the michaelites To popularize the relevant knowledge and technology of artificial cornea, bring light and hope for the safe and effective clinical development of artificial cornea, bring light and hope to the majority of corneal blind patients, and contribute wisdom and strength to the realization of healthy China.
On such a special day, the meeting was transferred to the "cloud". Although the opportunity of face-to-face communication was lost, it also broke the regional restrictions. Ophthalmologists can also talk about the development of artificial cornea, exchange and learn from each other, share experience and achievements, and jointly explore the innovative development road of corneal blindness diagnosis and treatment!